Anti-Gd2-Car Engineered T Cells
Neuroblastoma
Shenzhen Geno-Immune Medical InstituteCell therapyPhase 1/2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 81/ 100
Competitive context
62 Active assets in the Neuroblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan National Cancer Institute (NCI) | Phase 2 | BB |
FILGRASTIM M.D. Anderson Cancer Center | Phase 4 | BB |
ETOPOSIDE M.D. Anderson Cancer Center | Phase 2/3 | BB |
Eloxatin National Cancer Institute (NCI) | Phase 2 | BB |
Cyclophosphamide Robbie Majzner | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Anti-Gd2-Car Engineered T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →